The quality and reproducibility of PubMed reports in general and assessing this for bioactive compounds in particular, are major themes that cannot be addressed here in detail. However, they are crucial determinants of the data mining quality ADEV teams need to strive for. The major problem is (even if we acknowledge the quality standards of the journals referred to above) that these are by no means shared with all 29.7 million articles indexed in PubMed. Even adding the marginal stringency for those journals passing the MEDLINE acceptance criteria only reduces the total to 25.8 million (see 'MEDLINE, PubMed, and PMC (PubMed Central): How are they different?' NIH link).